HTG Molecular Diagnostics Reports First Quarter 2019 Results
Call scheduled for today, May 9, at 4:30pm ET
TUCSON, Ariz., May 09, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today reported its financial results for the first quarter ended March 31, 2019.
Recent Accomplishments & Highlights:
- Achieved product and product-related services revenue of $2.7 million for the three months ended March 31, 2019, which represents a 54% increase over the same period in 2018 and reflects growth in both research use only (RUO) and molecular diagnostics (MDx) profiling revenue.
- Launched the HTG EdgeSeq Mouse mRNA Tumor Response Panel, which measures over 1,600 mouse mRNA targets in one RNA extraction-free assay, in the United States and Europe. This RUO profiling panel is designed for use in mouse oncology models to identify and quantify expression of genes and gene pathways from a variety of sample types.
- Obtained recertification to ISO 13485:2016 valid through May 2021.
- Announced an amendment to the IVD Test Development and Component Supply Agreement with Illumina to enable the expansion of potential fields for development and commercialization of IVD test kits for use with HTG EdgeSeq and Illumina sequencing technology. Under the amended agreement, HTG may now submit potential development plans to Illumina for consideration in the fields of autoimmune, cardiovascular and fibrosis disorders and diseases in addition to development plans in the oncology field.
“We entered 2019 with continued growth and strong performance in our RUO profiling business and are beginning to see the momentum that we have anticipated in our MDx business,” said John Lubniewski, President and CEO of HTG. “Collaborative development services revenue declined as expected this quarter due to reduced activity in our two active PDP development programs, which were awaiting go-forward decisions during the period. Our profiling revenue reflects positive growth in both our biopharmaceutical customers' project pipelines and expansion of our relationships with academic medical centers in the United States and Europe.”
First Quarter 2019 Financial Results:
Total revenue for the first quarter of 2019 was $3.2 million compared to $4.2 million for the same period in 2018. Product and product-related services revenue for the first quarter of 2019 was $2.7 million compared to $1.7 million in the same period in 2018 and collaborative development services revenue for the first quarter of 2019 was $0.5 million compared to $2.4 million in the same period in 2018.
Net loss from operations for the first quarter of 2019 was $5.3 million, compared to $5.2 million for the first quarter of 2018. Net loss per share was $(0.19) for the first quarter of 2019 compared to $(0.22) for the first quarter of 2018.
HTG ended the first quarter with $25.0 million in cash, cash equivalents and short-term available-for-sale securities and current liabilities of approximately $4.8 million plus an additional $15.6 million in non-current liabilities. An additional $3.3 million of restricted cash was held in connection with a convertible note that is included in non-current liabilities as of March 31, 2019.
Conference Call and Webcast:
HTG will host an investment community conference call today beginning at 4:30 p.m. Eastern Time. Conference call and webcast details follow:
| Date: | Thursday, May 9, 2019 | |
| Time: | 4:30pm Eastern Time | |
| Toll Free: | (888) 221-3881 | |
| International: | (323) 794-2590 | |
| Conference ID: | 4490665 | |
| Webcast: | http://public.viavid.com/index.php?id=134341 |
About HTG:
HTG is focused on NGS-based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. The company’s mission is to empower precision medicine at the local level.
Safe Harbor Statement:
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected growth of our various lines of business. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, the risk that our amended agreement with Illumina may not provide the expected benefits; the risk that we may not realize the benefits expected under our collaboration agreements; risks associated with our ability to successfully commercialize our products; the risk that our products and services may not be adopted by biopharmaceutical companies or other customers as anticipated, or at all; our ability to manufacture our products to meet demand; the level and availability of third party payor reimbursement for our products; our ability to effectively manage our anticipated growth; our ability to protect our intellectual property rights and proprietary technologies; our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; competition in our industry; additional capital and credit availability; our ability to attract and retain qualified personnel; and product liability claims. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
-Financial tables follow-
| HTG Molecular Diagnostics, Inc. | ||||||||
| Consolidated Statements of Operations | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2019 | 2018 | |||||||
| Revenue: | ||||||||
| Product and product-related services | $ | 2,662,505 | $ | 1,733,546 | ||||
| Collaborative development services | 540,320 | 2,425,106 | ||||||
| Total revenue | 3,202,825 | 4,158,652 | ||||||
| Operating expenses: | ||||||||
| Cost of product and product-related services revenue | 2,045,527 | 1,137,063 | ||||||
| Selling, general and administrative | 4,400,866 | 5,657,832 | ||||||
| Research and development | 2,074,748 | 2,589,286 | ||||||
| Total operating expenses | 8,521,141 | 9,384,181 | ||||||
| Operating loss | (5,318,316 | ) | (5,225,529 | ) | ||||
| Loss on settlement of Growth Term Loan | — | (105,064 | ) | |||||
| Interest income (expense) | (52,530 | ) | (49,354 | ) | ||||
| Net loss | $ | (5,370,846 | ) | $ | (5,379,947 | ) | ||
| Net loss per share, basic and diluted | $ | (0.19 | ) | $ | (0.22 | ) | ||
| Shares used in computing net loss per share, basic and diluted | 28,600,679 | 24,704,128 | ||||||
| HTG Molecular Diagnostics, Inc. | |||||||
| Consolidated Balance Sheets | |||||||
| March 31, | December 31, | ||||||
| 2019 | 2018 | ||||||
| Assets | (Unaudited) | ||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 6,975,080 | $ | 8,432,600 | |||
| Short-term investments available-for-sale, at fair value | 18,056,673 | 22,681,049 | |||||
| Accounts receivable | 3,349,850 | 5,012,678 | |||||
| Inventory, net | 1,179,041 | 1,306,609 | |||||
| Prepaid expenses and other | 557,521 | 568,209 | |||||
| Total current assets | 30,118,165 | 38,001,145 | |||||
| Restricted cash | 3,270,247 | 3,270,247 | |||||
| Deferred offering costs | 198,088 | 59,030 | |||||
| Deferred MidCap revolving loan costs | 63,099 | 67,068 | |||||
| Right-of-use assets, net | 621,429 | — | |||||
| Property and equipment, net | 2,141,107 | 2,373,790 | |||||
| Total assets | $ | 36,412,135 | $ | 43,771,280 | |||
| Liabilities and stockholders' deficit | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 1,414,478 | $ | 1,849,921 | |||
| Accrued liabilities | 1,329,686 | 3,358,465 | |||||
| Contract liabilities - current | 246,009 | 332,711 | |||||
| NuvoGen obligation - current | 1,232,884 | 1,290,234 | |||||
| Operating lease liabilities - current | 478,804 | — | |||||
| Other current liabilities | 79,091 | 186,043 | |||||
| Total current liabilities | 4,780,952 | 7,017,374 | |||||
| NuvoGen obligation - non-current, net of discount | 5,292,769 | 5,702,519 | |||||
| Convertible note, related party - net of debt issuance costs | 2,977,577 | 2,974,213 | |||||
| MidCap Term Loan payable - net of discount and debt issuance costs | 6,739,815 | 6,704,641 | |||||
| Operating lease liabilities - non-current, net of discount | 441,338 | — | |||||
| Other non-current liabilities | 148,751 | 280,471 | |||||
| Total liabilities | 20,381,202 | 22,679,218 | |||||
| Commitments and Contingencies | |||||||
| Total stockholders’ equity | 16,030,933 | 21,092,062 | |||||
| Total liabilities and stockholders' equity (deficit) | $ | 36,412,135 | $ | 43,771,280 | |||
Contact:
Ashley Robinson
LifeSci Advisors, LLC
Phone: (617) 535-7742
Email: arr@lifesciadvisors.com
